Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · December 05, 2023

Time for Personalized Dosing of Natalizumab

Journal of Neurology, Neurosurgery, and Psychiatry


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Neurology, Neurosurgery, and Psychiatry
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)
J. Neurol. Neurosurg. Psychiatr. 2023 Nov 14;[EPub Ahead of Print], AA Toorop, ZY van Lierop, LM Gelissen, E Hoitsma, EM Zeinstra, LC van Rooij, CE van Munster, A Vennegoor, JP Mostert, BH Wokke, NF Kalkers, EL Hoogervorst, JJ van Eijk, CM Roosendaal, JJ Kragt, M Eurelings, J van Genugten, J Nielsen, L Sinnige, ME Kloosterziel, EP Arnoldus, GW van Dijk, WH Bouvy, MH Wessels, L Boonkamp, EM Strijbis, BW van Oosten, BA De Jong, BI Lissenberg-Witte, F Barkhof, B Moraal, CE Teunissen, T Rispens, BM Uitdehaag, J Killestein, ZL van Kempen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading